Bradanicline

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in Module:Infobox at line 314: malformed pattern (missing ']').

Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [1] Phase I clinical trials were completed successfully, and it was in phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[3] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[4] It was being studied for cognitive and memory enhancement.[5]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[6] It was also discontinued for ADHD, and no longer seems to be being developed.[6]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
  1. ↑ TC-5619 Cognitive Dysfunction in Schizophrenia
  2. ↑ Rethinking Schizophrenia
  3. ↑ Targacept retains full development rights for TC-5619
  4. ↑ Targacept ends development of ADHD drug
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ 6.0 6.1 http://adisinsight.springer.com/drugs/800026693
Retrieved from "https://infogalactic.com/w/index.php?title=Bradanicline&oldid=701790238"